Patent · US Active

Phosphorylated A2A receptor agonists

US9505796B2 · kind B2 · utility

2Cited by

6References

21Claims

0Family size

Assignee

Crozet Medical GmbH · DE

Inventors

Jurgen Schrader · Stuttgart, DE
Christa E. Müller · Bonn, DE
Ali El-Tayeb · Bonn, DE
Jamshed Iqbal · Bonn, DE

Key dates

Filing date	Dec 16, 2013
Grant date	Nov 29, 2016
Priority date	—
Expiry date	Dec 16, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P37/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A phosphorylated A2A receptor agonist providing agonist properties on the A2A receptor after dephosphorylation the phosphorylated A2A receptor agonist comprises a ribosyl moiety and a purine moiety and being phosphorylated at the 5′-position of the ribose moiety except adenosine monophosphate (AMP), adenosine diphosphate (ADP) or adenosine triphosphate (ATP), a medicament containing the compound of the invention including ADP and the use of the compound of the invention including ATP and ADP for several medical indications e.g. inflammatory events. In particular, compounds of formula (I) are also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.